Treatment Efficacy of PD-1 Inhibitor Therapy in Patients With Recurrent and/or Metastatic Salivary Gland Carcinoma

Kazuki Hashimoto; Ryuji Yasumatsu; Ryosuke Kuga; Takahiro Hongo; Hidetaka Yamamoto; Mioko Matsuo; Takahiro Wakasaki; Rina Jiromaru; Tomomi Manako; Satoshi Toh; Muneyuki Masuda; Moriyasu Yamauchi; Yuichiro Kuratomi; Hideoki Uryu; Torahiko Nakashima; Akihiro Tamae; Risa Tanaka; masahiko taura; Toranoshin Takeuchi; Takamasa Yoshida; Takashi Nakagawa

doi:10.21873/anticanres.15558

Treatment Efficacy of PD-1 Inhibitor Therapy in Patients With Recurrent and/or Metastatic Salivary Gland Carcinoma

Kazuki Hashimoto, Ryuji Yasumatsu, Ryosuke Kuga, Takahiro Hongo, Hidetaka Yamamoto, Mioko Matsuo, Takahiro Wakasaki, Rina Jiromaru, Tomomi Manako, Satoshi Toh, Muneyuki Masuda, Moriyasu Yamauchi, Yuichiro Kuratomi, Hideoki Uryu, Torahiko Nakashima, Akihiro Tamae, Risa Tanaka, masahiko taura, Toranoshin Takeuchi, Takamasa YoshidaTakashi Nakagawa

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Background/Aim: The efficacy of programmed cell death 1 (PD-1) inhibitor therapy for patients with recurrent and/or metastatic salivary gland carcinoma (R/M SGC) remains unclear. Patients and Methods: We retrospectively analyzed 36 patients with R/M SGC treated with PD-1 inhibitor. The expression of programmed cell death ligand 1 (PD-L1) and mismatch repair (MMR) proteins was also analyzed. Results: The objective response rate (ORR) was 11.1%. The histopathological subtypes of patients who achieved complete response or partial response were salivary duct carcinoma (SDC) in three patients and poorly differentiated carcinoma in one patient, all of whom showed a positive PD-L1 expression. The expression of MMR proteins was not associated with the efficacy of PD-1 inhibitors. Conclusion: Although the efficacy of PD-1 inhibitor therapy in R/M SGC is limited, certain patients may respond and achieve long-term disease control. There is a potential therapeutic effect in SDC patients with positive PD-L1 expression.

Original language	English
Pages (from-to)	981-989
Number of pages	9
Journal	Anticancer research
Volume	42
Issue number	2
DOIs	https://doi.org/10.21873/anticanres.15558
Publication status	Published - Feb 2022

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21873/anticanres.15558

Cite this

Hashimoto, K., Yasumatsu, R., Kuga, R., Hongo, T., Yamamoto, H., Matsuo, M., Wakasaki, T., Jiromaru, R., Manako, T., Toh, S., Masuda, M., Yamauchi, M., Kuratomi, Y., Uryu, H., Nakashima, T., Tamae, A., Tanaka, R., taura, M., Takeuchi, T., ... Nakagawa, T. (2022). Treatment Efficacy of PD-1 Inhibitor Therapy in Patients With Recurrent and/or Metastatic Salivary Gland Carcinoma. Anticancer research, 42(2), 981-989. https://doi.org/10.21873/anticanres.15558

Hashimoto, K, Yasumatsu, R, Kuga, R, Hongo, T, Yamamoto, H, Matsuo, M, Wakasaki, T, Jiromaru, R, Manako, T, Toh, S, Masuda, M, Yamauchi, M, Kuratomi, Y, Uryu, H, Nakashima, T, Tamae, A, Tanaka, R, taura, M, Takeuchi, T, Yoshida, T & Nakagawa, T 2022, 'Treatment Efficacy of PD-1 Inhibitor Therapy in Patients With Recurrent and/or Metastatic Salivary Gland Carcinoma', Anticancer research, vol. 42, no. 2, pp. 981-989. https://doi.org/10.21873/anticanres.15558

@article{77261ecec9804a699730c1214f1de523,

title = "Treatment Efficacy of PD-1 Inhibitor Therapy in Patients With Recurrent and/or Metastatic Salivary Gland Carcinoma",

abstract = "Background/Aim: The efficacy of programmed cell death 1 (PD-1) inhibitor therapy for patients with recurrent and/or metastatic salivary gland carcinoma (R/M SGC) remains unclear. Patients and Methods: We retrospectively analyzed 36 patients with R/M SGC treated with PD-1 inhibitor. The expression of programmed cell death ligand 1 (PD-L1) and mismatch repair (MMR) proteins was also analyzed. Results: The objective response rate (ORR) was 11.1%. The histopathological subtypes of patients who achieved complete response or partial response were salivary duct carcinoma (SDC) in three patients and poorly differentiated carcinoma in one patient, all of whom showed a positive PD-L1 expression. The expression of MMR proteins was not associated with the efficacy of PD-1 inhibitors. Conclusion: Although the efficacy of PD-1 inhibitor therapy in R/M SGC is limited, certain patients may respond and achieve long-term disease control. There is a potential therapeutic effect in SDC patients with positive PD-L1 expression.",

author = "Kazuki Hashimoto and Ryuji Yasumatsu and Ryosuke Kuga and Takahiro Hongo and Hidetaka Yamamoto and Mioko Matsuo and Takahiro Wakasaki and Rina Jiromaru and Tomomi Manako and Satoshi Toh and Muneyuki Masuda and Moriyasu Yamauchi and Yuichiro Kuratomi and Hideoki Uryu and Torahiko Nakashima and Akihiro Tamae and Risa Tanaka and masahiko taura and Toranoshin Takeuchi and Takamasa Yoshida and Takashi Nakagawa",

note = "Funding Information: The English usage in this article was reviewed by Japan Medical Communication. Inc. This work was supported by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science, Tokyo, (JSPS KAKENHI; Grant Number 17K16921; K Hashimoto). Publisher Copyright: {\textcopyright} 2022 International Institute of Anticancer Research. All rights reserved.",

year = "2022",

month = feb,

doi = "10.21873/anticanres.15558",

language = "English",

volume = "42",

pages = "981--989",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "2",

}

TY - JOUR

T1 - Treatment Efficacy of PD-1 Inhibitor Therapy in Patients With Recurrent and/or Metastatic Salivary Gland Carcinoma

AU - Hashimoto, Kazuki

AU - Yasumatsu, Ryuji

AU - Kuga, Ryosuke

AU - Hongo, Takahiro

AU - Yamamoto, Hidetaka

AU - Matsuo, Mioko

AU - Wakasaki, Takahiro

AU - Jiromaru, Rina

AU - Manako, Tomomi

AU - Toh, Satoshi

AU - Masuda, Muneyuki

AU - Yamauchi, Moriyasu

AU - Kuratomi, Yuichiro

AU - Uryu, Hideoki

AU - Nakashima, Torahiko

AU - Tamae, Akihiro

AU - Tanaka, Risa

AU - taura, masahiko

AU - Takeuchi, Toranoshin

AU - Yoshida, Takamasa

AU - Nakagawa, Takashi

N1 - Funding Information: The English usage in this article was reviewed by Japan Medical Communication. Inc. This work was supported by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science, Tokyo, (JSPS KAKENHI; Grant Number 17K16921; K Hashimoto). Publisher Copyright: © 2022 International Institute of Anticancer Research. All rights reserved.

PY - 2022/2

Y1 - 2022/2

N2 - Background/Aim: The efficacy of programmed cell death 1 (PD-1) inhibitor therapy for patients with recurrent and/or metastatic salivary gland carcinoma (R/M SGC) remains unclear. Patients and Methods: We retrospectively analyzed 36 patients with R/M SGC treated with PD-1 inhibitor. The expression of programmed cell death ligand 1 (PD-L1) and mismatch repair (MMR) proteins was also analyzed. Results: The objective response rate (ORR) was 11.1%. The histopathological subtypes of patients who achieved complete response or partial response were salivary duct carcinoma (SDC) in three patients and poorly differentiated carcinoma in one patient, all of whom showed a positive PD-L1 expression. The expression of MMR proteins was not associated with the efficacy of PD-1 inhibitors. Conclusion: Although the efficacy of PD-1 inhibitor therapy in R/M SGC is limited, certain patients may respond and achieve long-term disease control. There is a potential therapeutic effect in SDC patients with positive PD-L1 expression.

AB - Background/Aim: The efficacy of programmed cell death 1 (PD-1) inhibitor therapy for patients with recurrent and/or metastatic salivary gland carcinoma (R/M SGC) remains unclear. Patients and Methods: We retrospectively analyzed 36 patients with R/M SGC treated with PD-1 inhibitor. The expression of programmed cell death ligand 1 (PD-L1) and mismatch repair (MMR) proteins was also analyzed. Results: The objective response rate (ORR) was 11.1%. The histopathological subtypes of patients who achieved complete response or partial response were salivary duct carcinoma (SDC) in three patients and poorly differentiated carcinoma in one patient, all of whom showed a positive PD-L1 expression. The expression of MMR proteins was not associated with the efficacy of PD-1 inhibitors. Conclusion: Although the efficacy of PD-1 inhibitor therapy in R/M SGC is limited, certain patients may respond and achieve long-term disease control. There is a potential therapeutic effect in SDC patients with positive PD-L1 expression.

UR - http://www.scopus.com/inward/record.url?scp=85123905889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85123905889&partnerID=8YFLogxK

U2 - 10.21873/anticanres.15558

DO - 10.21873/anticanres.15558

M3 - Article

C2 - 35093898

AN - SCOPUS:85123905889

SN - 0250-7005

VL - 42

SP - 981

EP - 989

JO - Anticancer Research

JF - Anticancer Research

IS - 2

ER -

Treatment Efficacy of PD-1 Inhibitor Therapy in Patients With Recurrent and/or Metastatic Salivary Gland Carcinoma

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this